PEGylated insulin Lispro, (LY2605541)-a new basal insulin analogue

Design of Non-Standard Insulin Analogs for the Treatment of Diabetes Mellitus

(2012) V. Pandyarajan et al.   Current Diabetes Reports

Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes: A randomized, crossover study

(2012) J. Rosenstock et al.   DIABETES CARE

A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin-Treated Patients With Type 2 Diabetes

(2012) R. M. Bergenstal et al.   DIABETES CARE

Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials

(2012) R. E. Ratner et al.   DIABETES OBESITY & METABOLISM

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

(2012) Simon Heller et al.   LANCET

Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin

(2012) Ib Jonassen et al.   PHARMACEUTICAL RESEARCH

Insulin Degludec in Type 1 Diabetes: A randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine

(2011) K. I. Birkeland et al.   DIABETES CARE

Insulin Detemir Reduces Weight Gain as a Result of Reduced Food Intake in Patients With Type 1 Diabetes

(2011) S. Zachariah et al.   DIABETES CARE

Does diabetes therapy influence the risk of cancer?

(2009) U. Smith et al.   DIABETOLOGIA

Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden

(2009) J. M. Jonasson et al.   DIABETOLOGIA

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

(2009) C. J. Currie et al.   DIABETOLOGIA

The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes

(2008) Mike A. Baxter   ACTA DIABETOLOGICA

Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVETM study

(2008) A. Dornhorst et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE